4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 7.87 USD -2.48% Market Closed
Market Cap: 409m USD
Have any thoughts about
4D Molecular Therapeutics Inc?
Write Note

Intrinsic Value

FDMT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one FDMT stock under the Base Case scenario is 1.08 USD. Compared to the current market price of 7.87 USD, 4D Molecular Therapeutics Inc is Overvalued by 86%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

FDMT Intrinsic Value
1.08 USD
Overvaluation 86%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
4D Molecular Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for FDMT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about FDMT?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about 4D Molecular Therapeutics Inc

Provide an overview of the primary business activities
of 4D Molecular Therapeutics Inc.

What unique competitive advantages
does 4D Molecular Therapeutics Inc hold over its rivals?

What risks and challenges
does 4D Molecular Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in 4D Molecular Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for 4D Molecular Therapeutics Inc.

Provide P/S
for 4D Molecular Therapeutics Inc.

Provide P/E
for 4D Molecular Therapeutics Inc.

Provide P/OCF
for 4D Molecular Therapeutics Inc.

Provide P/FCFE
for 4D Molecular Therapeutics Inc.

Provide P/B
for 4D Molecular Therapeutics Inc.

Provide EV/S
for 4D Molecular Therapeutics Inc.

Provide EV/GP
for 4D Molecular Therapeutics Inc.

Provide EV/EBITDA
for 4D Molecular Therapeutics Inc.

Provide EV/EBIT
for 4D Molecular Therapeutics Inc.

Provide EV/OCF
for 4D Molecular Therapeutics Inc.

Provide EV/FCFF
for 4D Molecular Therapeutics Inc.

Provide EV/IC
for 4D Molecular Therapeutics Inc.

Show me price targets
for 4D Molecular Therapeutics Inc made by professional analysts.

What are the Revenue projections
for 4D Molecular Therapeutics Inc?

How accurate were the past Revenue estimates
for 4D Molecular Therapeutics Inc?

What are the Net Income projections
for 4D Molecular Therapeutics Inc?

How accurate were the past Net Income estimates
for 4D Molecular Therapeutics Inc?

What are the EPS projections
for 4D Molecular Therapeutics Inc?

How accurate were the past EPS estimates
for 4D Molecular Therapeutics Inc?

What are the EBIT projections
for 4D Molecular Therapeutics Inc?

How accurate were the past EBIT estimates
for 4D Molecular Therapeutics Inc?

Compare the revenue forecasts
for 4D Molecular Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of 4D Molecular Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of 4D Molecular Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of 4D Molecular Therapeutics Inc compared to its peers.

Compare the P/E ratios
of 4D Molecular Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing 4D Molecular Therapeutics Inc with its peers.

Analyze the financial leverage
of 4D Molecular Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for 4D Molecular Therapeutics Inc.

Provide ROE
for 4D Molecular Therapeutics Inc.

Provide ROA
for 4D Molecular Therapeutics Inc.

Provide ROIC
for 4D Molecular Therapeutics Inc.

Provide ROCE
for 4D Molecular Therapeutics Inc.

Provide Gross Margin
for 4D Molecular Therapeutics Inc.

Provide Operating Margin
for 4D Molecular Therapeutics Inc.

Provide Net Margin
for 4D Molecular Therapeutics Inc.

Provide FCF Margin
for 4D Molecular Therapeutics Inc.

Show all solvency ratios
for 4D Molecular Therapeutics Inc.

Provide D/E Ratio
for 4D Molecular Therapeutics Inc.

Provide D/A Ratio
for 4D Molecular Therapeutics Inc.

Provide Interest Coverage Ratio
for 4D Molecular Therapeutics Inc.

Provide Altman Z-Score Ratio
for 4D Molecular Therapeutics Inc.

Provide Quick Ratio
for 4D Molecular Therapeutics Inc.

Provide Current Ratio
for 4D Molecular Therapeutics Inc.

Provide Cash Ratio
for 4D Molecular Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for 4D Molecular Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for 4D Molecular Therapeutics Inc?

What is the current Free Cash Flow
of 4D Molecular Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for 4D Molecular Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
4D Molecular Therapeutics Inc

Current Assets 552.6m
Cash & Short-Term Investments 541.9m
Other Current Assets 10.7m
Non-Current Assets 67.5m
Long-Term Investments 35.7m
PP&E 29.4m
Other Non-Current Assets 2.3m
Current Liabilities 19.4m
Accounts Payable 3.4m
Accrued Liabilities 14m
Other Current Liabilities 2m
Non-Current Liabilities 12.4m
Other Non-Current Liabilities 12.4m
Efficiency

Earnings Waterfall
4D Molecular Therapeutics Inc

Revenue
41m USD
Operating Expenses
-248.4m USD
Operating Income
-207.4m USD
Other Expenses
29m USD
Net Income
-178.5m USD

Free Cash Flow Analysis
4D Molecular Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

FDMT Profitability Score
Profitability Due Diligence

4D Molecular Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
Declining ROIC
19/100
Profitability
Score

4D Molecular Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

FDMT Solvency Score
Solvency Due Diligence

4D Molecular Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

4D Molecular Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FDMT Price Targets Summary
4D Molecular Therapeutics Inc

Wall Street analysts forecast FDMT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FDMT is 51 USD with a low forecast of 36.36 USD and a high forecast of 86.1 USD.

Lowest
Price Target
36.36 USD
362% Upside
Average
Price Target
51 USD
548% Upside
Highest
Price Target
86.1 USD
994% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for FDMT?

Click here to dive deeper.

Dividends

4D Molecular Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for FDMT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

FDMT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

408.6m USD

Dividend Yield

0%

Description

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2020-12-11. The firm is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The firm's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The firm is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).

Contact

CALIFORNIA
Emeryville
5858 Horton Street #455, Emeryville
+15105052680.0
www.4dmoleculartherapeutics.com

IPO

2020-12-11

Employees

124

Officers

Executive Chairman
Dr. John F. Milligan Ph.D.
Co-Founder, CEO & Director
Dr. David H. Kirn M.D.
President & COO
Dr. Fariborz Kamal Ph.D.
Chief Scientific Officer
Dr. Noriyuki Kasahara M.D., Ph.D.
Chief Medical Officer
Dr. Robert Y. Kim M.B.A., M.D.
Co-Founder & Chief of Staff
Ms. Theresa Janke
Show More
Chief Financial & Business Officer
Mr. Uneek Mehra
Chief Legal Officer & Corporate Secretary
Dr. Scott P. Bizily J.D., Ph.D.
Chief Development Officer
Dr. An Song Ph.D.
Senior VP & Therapeutic Area Head of Pulmonology
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one FDMT stock?

The intrinsic value of one FDMT stock under the Base Case scenario is 1.08 USD.

Is FDMT stock undervalued or overvalued?

Compared to the current market price of 7.87 USD, 4D Molecular Therapeutics Inc is Overvalued by 86%.

Back to Top